HSP Key Stats
| Income Statement | |
| Revenue TTM | 4.010B |
| Revenue Quarterly YoY Growth | -8.48% |
| EPS Diluted TTM | -0.4381 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -72.60M |
| Profitability | |
| Gross Profit Margin Quarterly | 16.98% |
| Profit Margin Quarterly | -8.67% |
| Dividend | |
| Dividend Yield | 0% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 5.931B |
| Enterprise Value | 7.074B |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 1.988 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.5851 |
| Free Cash Flow | -55.70M |
| Return on Equity | -2.41% |
HSP News
- This Blockbuster Biologic May Face a Steep Cliff Fool Jun 18
- Is This Hurting Healthcare Company Priced for a Recovery? Jun 14
- Is This Hurting Healthcare Company Priced for a Recovery? Fool Jun 13
- UPDATE: Mylan (MYL) Chairman Says Good Time for Consolidating in Generic Drugs Street Insider Jun 12
- ICU Medical draws interest from CareFusion as bids loom -sources Jun 7
- Hospira: A Case Study For Strategic Valuation Jun 6
- Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response... Jun 3
- FDA raises concerns at Hospira facility in Tamil Nadu May 30
- FDA raises drug safety concerns at Hospira facility in India May 30
- Hospira (HSP) Receives FDA Warning Letter for Irungattukottai Facility Street Insider May 30
HSP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Hospira is up 6.29% over the last year vs S&P 500 Total Return up 23.89%, Cumberland Pharmaceuticals down 20.63%, and Mylan up 48.50%.
HSP Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these HSP related companies
Pro Ratings for HSP
Pro Report PDF for HSP
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download HSP Pro Report PDF
Pro Strategies Featuring HSP
Did Hospira make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
HSP Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Hospira, Inc. is a U.S.-based global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It has approximately 15,000 employees. Hospira is the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories.
Other HSP Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| HSP | 35.84 | -0.75 | -2.05% | 5.931B |
